Skip to content

Viral delivery particles may persist in the retina for up to 6 years

Recent advances in retinal gene therapy, notably in three concurrent human trials addressing LCA (Leber’s congenital amurosis), have focused significant attention on the wider potential to apply such technologies to other diseases, both within and beyond the field of ophthalmology.